RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
| Parameter | Recommendation |
|
Starting dose
|
2 mg patch applied once daily (evening application preferred) |
|
Titration
|
Usually not required |
|
Usual maintenance dose
|
2 mg patch once daily |
|
Maximum dose
|
2 mg/day |
| Parameter | Recommendation |
|
Starting dose
|
2 mg patch once daily |
|
Titration
|
Not required |
|
Usual maintenance dose
|
2 mg once daily |
|
Maximum dose
|
2 mg/day |
| Age Group | Starting Dose | Titration | Usual Maintenance | Maximum Dose |
|
6–11 years
|
1 mg patch once daily | Not required | 1 mg once daily | 1 mg/day |
|
≥12 years (Adolescents)
|
2 mg patch once daily | Not required | 2 mg once daily | 2 mg/day |
| Renal Function | Recommendation |
| Mild–Moderate impairment | No dose adjustment required |
| Severe impairment (eGFR <30 mL/min) | Limited data; use with caution; monitor for systemic β2-agonist effects |
| Haemodialysis | No specific data; monitor clinically |
| Child-Pugh Class | Score | Recommendation |
|
Class A (Mild)
|
5–6 points | No dose adjustment required |
|
Class B (Moderate)
|
7–9 points | Use with caution; monitor for β2-agonist adverse effects |
|
Class C (Severe)
|
10–15 points | Avoid use unless benefit clearly outweighs risk; increased systemic exposure possible |
| Aspect | Details |
|
Overall safety
|
Limited human data; animal studies suggest potential β2-agonist related risks |
|
When to use
|
Only if clearly needed and benefit outweighs potential risk; specialist guidance required |
|
Preferred alternatives
|
Inhaled salmeterol or formoterol combined with ICS (more established safety data) |
|
Monitoring required
|
Maternal: heart rate, blood pressure. Fetal: heart rate monitoring if chronic use in late pregnancy |
| Aspect | Details |
|
Compatibility
|
Likely compatible — low systemic bioavailability from transdermal route |
|
Expected levels in milk
|
Low (minimal systemic absorption expected) |
|
Preferred alternatives
|
Inhaled LABAs (salmeterol, formoterol) if available |
|
Infant monitoring
|
Observe for irritability, sleep disturbances, tachycardia (unlikely with transdermal use) |
| Aspect | Recommendation |
|
Starting dose
|
2 mg patch once daily (same as adult dose) |
|
Titration
|
Not required; slower onset of clinical response may occur |
|
Extra risks
|
Increased sensitivity to tremor, tachycardia, electrolyte disturbances; underlying cardiovascular disease may be exacerbated |
|
Monitoring
|
Heart rate, blood pressure, serum potassium if on concurrent diuretics or corticosteroids |
|
Practical tips
|
Transdermal route advantageous in elderly with poor inhaler technique; ensure adequate skin integrity at application site |
| Interacting Drug | Effect/Risk | Management |
|
Non-selective β-blockers (propranolol, carvedilol)
|
Antagonise bronchodilator effect; may precipitate bronchospasm | Avoid combination; if β-blocker essential, use cardioselective agent (bisoprolol, metoprolol) |
|
MAO inhibitors (phenelzine, tranylcypromine, linezolid)
|
Potentiate cardiovascular effects; risk of hypertension, arrhythmias | Avoid combination or use with extreme caution |
|
Tricyclic antidepressants (amitriptyline, imipramine)
|
Potentiate cardiovascular effects | Use with caution; monitor heart rate and rhythm |
|
QT-prolonging drugs (haloperidol, amiodarone, ondansetron)
|
Additive risk of arrhythmias, especially with hypokalaemia | Monitor ECG; correct electrolytes before and during treatment |
|
Other LABAs (salmeterol, formoterol)
|
Additive β2-agonist effects; increased risk of cardiovascular adverse effects | Avoid concurrent use of multiple LABAs |
| Interacting Drug | Effect/Risk | Management |
|
Loop diuretics (furosemide)
|
Additive hypokalaemia risk | Monitor serum potassium; supplement if necessary |
|
Thiazide diuretics
|
Additive hypokalaemia risk | Monitor potassium levels |
|
Systemic corticosteroids
|
Enhanced hypokalaemia risk; may potentiate hyperglycaemia | Monitor electrolytes and blood glucose |
|
Inhaled corticosteroids
|
Generally beneficial combination; minor hypokalaemia risk | Standard combination; monitor potassium with high doses |
|
Xanthines (theophylline)
|
Additive stimulatory effects; increased tremor, tachycardia | Monitor for adverse effects; may need dose adjustment |
|
Short-acting β2-agonists (salbutamol)
|
Additive cardiovascular effects with frequent rescue use | Acceptable for rescue; excessive SABA use indicates poor control |
|
Digoxin
|
Hypokalaemia from β2-agonist may increase digoxin toxicity | Monitor potassium and digoxin levels |
| Adverse Effect | Notes |
| Paradoxical bronchospasm | Discontinue immediately; provide alternative bronchodilator |
| Tachyarrhythmias (SVT, atrial fibrillation) | May require hospitalisation and drug discontinuation |
| Severe hypokalaemia | Monitor potassium; may precipitate arrhythmias |
| Severe skin hypersensitivity reactions | Remove patch immediately; discontinue drug; do not rechallenge |
| Anaphylaxis | Rare; requires immediate management and permanent discontinuation |
| Angina/myocardial ischaemia | In patients with underlying coronary artery disease |
| Timing | Parameters |
|
Baseline
|
Heart rate, blood pressure, respiratory status, blood glucose (in diabetics), serum potassium (if on diuretics/corticosteroids), skin integrity at application sites |
|
After initiation (1–2 weeks)
|
Heart rate, tremor assessment, symptom control, skin site inspection |
|
Long-term
|
Periodic serum potassium (especially if on corticosteroids/diuretics), lung function testing (spirometry), reassessment of asthma/COPD control, skin condition at application sites |
| Formulation | Price Range | Notes |
| 0.5 mg patch | ₹25–₹35 per patch | Paediatric strength |
| 1 mg patch | ₹30–₹45 per patch | Paediatric/lower adult dose |
| 2 mg patch | ₹55–₹70 per patch | Standard adult dose |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.